NephroPlus, Asia’s largest dialysis service provider and globally the fifth-largest by treatment volumes in FY25, will open its Initial Public Offering (IPO) on Wednesday, December 10, with the issue closing Friday, December 12. The price band has been set at ₹438–₹460 per equity share, including a ₹41 discount for eligible employees.
The public issue will include a fresh equity component of ₹353.4 crore and an offer for sale of 1,12,53,102 shares.
The company intends to deploy ₹129.1 crore toward capital expenditure for new dialysis clinics across India and allocate ₹136 crore toward scheduled repayment or pre-payment of borrowings.
Established in 2009, NephroPlus operates the largest organised dialysis network in India, covering 288 cities in 21 states and 4 Union Territories. Its international footprint includes 519 clinics, with 51 centres in the Philippines, Uzbekistan and Nepal. The 165-bed Tashkent dialysis clinic remains the largest in the world.
The company offers a wide spectrum of services—haemodialysis, home haemodialysis, hemodiafiltration, holiday dialysis, dialysis on call, and dialysis on wheels—to ensure convenience and accessibility.
India’s dialysis market, valued at USD 818 million in FY24, is set to expand to USD 1,979 million by 2029.
